Crohn's-disease, treatmentNatalizumab, therapeutic use
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of ...
Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031–2045.e2011. doi:10.1016/j.cgh.2020.10.039 16. Amiot A, Peyrin-Biroulet L. Current, new a...
Juvenile Idiopathic Inflammatory Myopathies (IIM) are a group of rare diseases that are heterogeneous in terms of pathology that can include proximal muscle weakness, associated skin changes and systemic involvement. Despite options for treatment, many patients continue to suffer resistant disease and l...
Crohn's disease; UC: Ulcerative colitis; Vit: Vitiligo; HPS: Hemophagocytic syndrome; GCA: Giant cell arteritis; NIU: Non-infectious uveitis; CLE: Cutaneous lupus erythematosus; LN: Lupus nephritis; DLE: Discoid lupus erythematosus; dSc: Diffuse scleroderma Supplementary Information The online version...
A urine oxalate (UOx) excretion of >0.5 mmol/1.73 m2/day is likely to be due to a metabolic cause although some secondary cases due toCrohn's disease,short gut syndromeandpancreatic insufficiencyhave grossly elevated oxalate excretions >1 mmol/1.73 m2/day. Urinaryglycolateexcretion may be rais...
This expert panel has addressed considerations in the diagnostic evaluation of gastroin- testinal symptoms in individuals with ASDs that may lead to effective treat- ment options, with the hope that pa- tients will have better access to en- lightened care. Important take-away messages are ...